Dr. Gail H. Cassell

• 
  newsletter.cmpi.org/December_03_2007.html - [Cached Version]
  Published on: 11/26/2007    Last Visited: 8/26/2008  

  A subcommittee of the FDA's Science Board (headed by the talented Dr. Gail Cassell of Eli Lilly & Company) says the agency suffers from a "plethora of inadequacies," including an "appallingly low" rate of food inspections and a lack of scientists who understand new technologies.

• 
  nextwave.sciencemag.org/career_development/previous_iss - [Cached Version]
  Published on: 2/8/2008    Last Visited: 2/16/2008  

  "Attention to career development and advancement is more part of the culture of industry than it is in academia," says Gail Cassell, who is vice president of scientific affairs at Eli Lilly and Company and was previously a department chair in microbiology at University of Alabama Schools of Medicine and Dentistry at Birmingham."Lilly certainly invests a lot of time and resources in nurturing the careers of females in both technical and management positions."
  
  Employees at Eli Lilly undergo evaluations twice a year and, in addition to being evaluated by their bosses, those in supervisory positions receive performance reviews from peers and the people they manage.With multiple inputs going into an employee's review, the process is more objective than the opinion of a single person, like one's boss.This continual feedback "improves the individual, improves the system, and builds a better relationship between employee and employer," says Cassell.
  ...
  "With our scientific talent pool being what it is today around the globe, you want that diversity to ensure success," Cassell says.

• 
  www.nj.com/news/index.ssf/2008/01/29/ - [Cached Version]
  Published on: 1/29/2008    Last Visited: 1/29/2008  

  'It is readily apparent that the FDA suffers from serious scientific deficiencies and is not able to meet its current or emerging regulatory responsibilities," said Gail Cassell, an Eli Lilly vice president and head of an internal FDA scientific advisory board that studied problems at the agency.
  
  'We have concluded that American lives are at risk," Cassell told the House Energy and Commerce investigations subcommittee.

• 
  www.fdanews.com/newsletter/article?issueId=11076&articl - [Cached Version]
  Published on: 12/5/2007    Last Visited: 12/5/2007  

  The subcommittee was cautioned against assessing the FDA's financial resources but could not review the agency's shortcomings without discussing resources, subcommittee Chairwoman Gail Cassell said.

• 
  www.sbs.ox.ac.uk/templates/templates/News/NewsItem.aspx - [Cached Version]
  Published on: 8/21/2005    Last Visited: 12/2/2007  

  Dr Gail Cassell, Vice President of Infectious Diseases at Eli Lily and Company

• 
  www.instituteofmedicine.org/CMS/3740/10303.aspx - [Cached Version]
  Published on: 9/11/2008    Last Visited: 9/11/2008  

  GAIL H. CASSELL is Vice President, Scientific Affairs, Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly & Company.Previously, she was the Charles H. McCauley Professor and (since 1987) Chair, Department of Microbiology, University of Alabama Schools of Medicine and Dentistry at Birmingham, a department which, under her leadership, has ranked first in research funding from the National Institutes of Health since 1989.She is a member of the Director's Advisory Committee of the Centers for Disease Control and Prevention.Dr. Cassell is past president of the American Society for Microbiology (ASM) and is serving her third three-year term as chairman of the Public and Scientific Affairs Board of ASM.She is a former member of the National Institutes of Health Director's Advisory Committee and a former member of the Advisory Council of the National Institute of Allergy and Infectious Diseases.She has also served as an advisor on infectious diseases and indirect costs of research to the White House Office on Science and Technology and was previously chair of the Board of Scientific Counselors of the National Center for Infectious Diseases, Centers for Disease Control and Prevention.Dr. Cassell served eight years on the Bacteriology-Mycology-II Study Section and served as its chair for three years.She serves on the editorial boards of several prestigious scientific journals and has authored over 275 articles and book chapters.She has been intimately involved in the establishment of science policy and legislation related to biomedical research and public health.Dr. Cassell has received several national and international awards and an honorary degree for her research on infectious diseases.

• 
  www.chicagotribune.com/business/chi-sun_baxter-heparin- - [Cached Version]
  Published on: 3/2/2008    Last Visited: 3/2/2008  

  The heparin case is a warning signal, said Gail Cassell, vice president of scientific affairs at drug giant Eli Lilly & Co.
  
  "Unless the deficiencies can be addressed rather urgently, this is not the last such situation," said Cassell.

• 
  www.rtmagazine.com/reuters_article.asp?id=20080430rglt0 - [Cached Version]
  Published on: 4/30/2008    Last Visited: 5/1/2008  

  That climate contributes to a turnover rate in key scientific areas -- twice as high as other government agencies, said Gail Cassell, an Eli Lilly and Co vice president who chaired the science board panel review of FDA.
  
  "People are a lot more attuned to the fact that the environment must be improved," she said.

• 
  www.personalinjurylawyeramerica.com/news_articles/2008/ - [Cached Version]
  Published on: 3/2/2008    Last Visited: 9/1/2008  

  The heparin case is a warning signal, said Gail Cassell, vice president of scientific affairs at drug giant Eli Lilly & Co."Unless the deficiencies can be addressed rather urgently, this is not the last such situation," said Cassell.

• 
  www.asm.org/Policy/index.asp?bid=52460 - [Cached Version]
  Published on: 8/28/2007    Last Visited: 11/20/2007  

  Gail H. Cassell, Ph.D., Chair, Committee on Biomedical Research

Page:  1 2 3 4 5